Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom ...

AstraZeneca advances its ambition to redefine cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, ...

BN001, a signal seeking Phase II randomized trial, indicated that photon radiation dose intensification (75 Gy) did not ...

Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to ...

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the Best Penny Stocks to Buy with the Highest Upside Potential. On September 8, ImmunityBio, Inc. (NASDAQ:IBRX) announced new findings from its Phase 2 ...

We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. ImmunityBio, Inc. is one of them.

A new review highlights sepsis-induced immunosuppression as a key driver of mortality, summarizing current research and ...

In 2025, there will be a complicated combination of opportunities and difficulties in the healthcare innovation landscape, ...

Shiong’s portfolio saw a slight drop over past 12 months as the value of his stake in Culver City immunotherapy firm ...

The nonoperative regimen led to a 2-year total mesorectal excision (TME)-free survival of 57% in 63 evaluable patients, and a ...

A new study finds that EULAR/ACR criteria identify more systemic lupus erythematosus cases among patients with interstitial ...